Gene therapy company Krystal Biotech raises $10 mln in private placement

Pittsburgh-based Krystal Biotech, a gene therapy company, has closed a private placement of $10 million. The buyer was Frazier Healthcare Partners. According to terms of the transaction, Krystal Biotech sold 625,000 shares of its stock at $16 per share. Chardan, an investment bank, served as the placement agent.

DealsNorth AmericaUSHealthcareBriefs